U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    33,647.12
    +1,377.13 (+4.27%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Why Forma Therapeutics (FMTX) Might Surprise This Earnings Season

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Investors are always looking for stocks that are poised to beat at earnings season and Forma Therapeutics Holdings, Inc. FMTX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Forma Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for FMTX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 77 cents per share for FMTX, compared to a broader Zacks Consensus Estimate of a loss of 79 cents per share. This suggests that analysts have very recently bumped up their estimates for FMTX, giving the stock a Zacks Earnings ESP of +2.53% heading into earnings season.

Forma Therapeutics Holdings, Inc. Price and EPS Surprise

Forma Therapeutics Holdings, Inc. Price and EPS Surprise
Forma Therapeutics Holdings, Inc. Price and EPS Surprise

Forma Therapeutics Holdings, Inc. price-eps-surprise | Forma Therapeutics Holdings, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that FMTX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Forma Therapeutics, and that a beat might be in the cards for the upcoming report.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 crypto-related stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Forma Therapeutics Holdings, Inc. (FMTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research